One of the most widely-used asthma and breathing treatments for over 20 years is being taken off the shelves in 2024, potentially leaving patients, healthcare providers and insurers scrambling.
The pharma giant appears to be skirting its own price cap through an arrangement with a generic manufacturer, Sen. Maggie Hassan charges Pharmaceutical giant GlaxoSmithKline is sidestepping its pledge ...
Boehringer Ingelheim GmbH’s and Astrazeneca plc’s implementation of a $35 monthly U.S. price cap on inhalers for asthma and chronic obstructive pulmonary disease is adding to the pressure on Prasco ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback